This is a non-core endpoint: only basic statistics are computed.
See its core counterpart CD2_INSITU_EAR_RESP_EXALLC for full statistics.
Carcinoma in situ of middle ear and respiratory system
CD2_INSITU_EAR_RESP
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
83 |
4. Check minimum number of eventsNone |
83 |
5. Include endpoints |
165 |
6. Filter based on genotype QC (FinnGen only) |
165 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 2
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D00-D09
- Name in latin
- Carcinoma in situ auris mediae sive systematis respiratorii
Similar endpoints
↥List of similar endpoints to
Carcinoma in situ of middle ear and respiratory system
based on the number of shared cases.
Similar with more cases:
- Carcinoma in situ of middle ear and respiratory system
- In situ neoplasms
- In situ neoplasms
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 165 | 44 | 121 |
| Unadjusted period prevalence (%) | 0.04 | 0.01 | 0.05 |
| Median age at first event (years) | 68.56 | 66.30 | 69.39 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 158
- Matched controls
- 1581
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D02.0
ICD-10 Finland
Carcinoma in situ: Larynx
+∞
52.0
47
*
C32.0
ICD-10 Finland
Malignant neoplasm: Glottis
214.2
46.6
46
*
DQB10
NOMESCO Finland
Endoscopic excision of lesion of larynx
58.2
39.9
46
11
DQA10
NOMESCO Finland
Biopsy of larynx
73.4
27.1
30
5
D14.1
ICD-10 Finland
Benign neoplasm: Larynx
61.2
26.3
30
6
ZXC10
NOMESCO Finland
Use of laser
34.6
24.3
31
11
UDQ12
NOMESCO Finland
Flexible laryngoscopy
15.8
24.0
40
33
D38.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Larynx
84.4
20.3
22
*
C32.9
ICD-10 Finland
Malignant neoplasm: Larynx, unspecified
+∞
20.2
19
*
J38.3
ICD-10 Finland
Other diseases of vocal cords
53.4
19.8
23
5
UDQ22
NOMESCO Finland
Microlaryngoscopy
60.1
18.5
21
*
8070/3-C32.9
ICD-O-3
Squamous cell carcinoma, NOS, of larynx, NOS
75.7
18.2
20
*
8070/2-C32.0
ICD-O-3
Squamous cell carcinoma in situ, NOS, of glottis
+∞
18.1
17
*
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
6.2
16.9
50
109
8140/2-C34.1
ICD-O-3
Adenocarcinoma in situ, NOS, of upper lobe, lung
+∞
15.9
15
*
UGC12
NOMESCO Finland
Flexible bronchoscopy
6.3
15.3
44
91
8070/3-C32.0
ICD-O-3
Squamous cell carcinoma, NOS, of glottis
+∞
14.8
14
*
C320, 8077, 2
ICD-O-3
NA
+∞
14.8
14
*
D38.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Trachea, bronchus and lung
9.5
14.4
30
38
J37.0
ICD-10 Finland
Chronic laryngitis
14.0
13.6
23
19
WF002
NOMESCO Finland
Radical radiotherapy
8.1
13.5
31
46
GD1CT
NOMESCO Finland
Biopsy of the lung with CT guidance
19.4
12.9
19
11
C34.12
ICD-10 Finland
Malignant tumor of the anterior, bronchial or pulmonary adenocarcinoma
25.2
11.8
16
7
D02.3
ICD-10 Finland
Carcinoma in situ: Other parts of respiratory system
+∞
11.6
11
*
D02.2
ICD-10 Finland
Carcinoma in situ: Bronchus and lung
+∞
11.6
11
*
DQB70
NOMESCO Finland
Total excision of vocal cord
+∞
11.6
11
*
XX3DW
NOMESCO Finland
Time consuming IT work
5.9
11.1
32
65
GDC01
NOMESCO Finland
Thoracoscopic lobectomy of lung
64.5
10.8
12
*
130
Kela drug reimbursment
Malignant tumour
4.7
10.3
37
97
GD1AD
NOMESCO Finland
Thorax CT examination
10.6
10.1
19
20
UJC01
NOMESCO Finland
Scopy of lower throat
21.8
10.0
14
7
EP1AE
NOMESCO Finland
Neck ultrasound examination
8.1
9.9
22
31
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
6.3
9.4
25
46
UDH02
NOMESCO Finland
Rhinopharyngoscopy
7.3
9.4
22
34
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
3.0
9.3
70
329
C34.90
ICD-10 Finland
Malignant tumor in unspecified location in bronchus and lung without histology
20.1
9.1
13
7
EN1BD
NOMESCO Finland
Very extensive CT examination of mouth and soft tissues of neck
15.2
8.9
14
10
DQB30
NOMESCO Finland
Laryngectomy
+∞
8.4
8
*
2310A
ICD-9 Finland
Carcinoma in situ of respiratory system, Larynx
+∞
8.4
8
*
UDQ02
NOMESCO Finland
Direct laryngoscopy
83.9
7.5
8
*
WX734
NOMESCO Finland
JET-ventilation
83.9
7.5
8
*
DQE00
NOMESCO Finland
Implantation of prosthetic replacement for larynx
83.9
7.5
8
*
8070/2-C32.9
ICD-O-3
Squamous cell carcinoma in situ, NOS, of larynx, NOS
+∞
7.3
7
*
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
16.8
7.3
11
7
WX404
NOMESCO Finland
Intravenous generell anesthesy
3.0
6.9
42
168
J44.8
ICD-10 Finland
Other specified chronic obstructive pulmonary disease
3.1
6.7
38
145
WZC30
NOMESCO Finland
Teaching
3.5
6.7
31
102
UJC02
NOMESCO Finland
Rigid oesophagoscopy
72.7
6.5
7
*
8140/2-C34.3
ICD-O-3
Adenocarcinoma in situ, NOS, of lower lobe, lung
+∞
6.3
6
*
C32.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of larynx
+∞
6.3
6
*
8070/2-C34.3
ICD-O-3
Squamous cell carcinoma in situ, NOS, of lower lobe, lung
+∞
6.3
6
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
6.0
6.2
16
29
WX408
NOMESCO Finland
General anesthesy, balanced
2.6
6.1
54
266
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
13
17
8.22
9.41
1.2
1.1
—
—
—
0
0
16
36
4.81
6.87
1.3
1.3
—
—
—
0
0
18
53
3.69
5.48
2.5
3.2
—
—
—
0
0
11
26
4.46
4.43
1.5
1.7
14.4
14.4
ug/l
0.00
11
26
10
26
4.03
3.58
1.7
2.0
—
—
—
0
0
66
438
1.84
3.48
4.3
3.3
2.3
2.3
mmol/l
0.22
58
370
8
16
5.20
3.09
1.9
1.5
—
—
—
0
0
88
656
1.73
3.01
7.3
7.0
1.2
1.2
mmol/l
0.03
79
547
11
35
3.30
2.99
1.5
1.9
—
—
—
0
0
79
582
1.69
2.75
4.9
4.4
—
—
—
0
0
11
37
3.11
2.75
1.5
1.5
—
—
—
0
0
8
19
4.37
2.71
1.1
1.3
—
—
—
0
0
7
15
4.82
2.62
1.9
1.5
—
—
—
0
0
89
686
1.65
2.54
11.2
10.3
4.6
4.3
e9/l
0.53
81
597
10
35
2.98
2.35
1.7
1.9
—
—
—
0
0
8
23
3.60
2.30
1.8
1.4
—
—
—
0
0
46
308
1.68
2.22
3.3
2.9
—
—
—
0
0
79
608
1.57
2.16
6.8
6.2
1.2
1.2
mmol/l
0.44
73
539
5
10
5.12
2.08
2.4
1.4
—
—
—
0
0
5
11
4.65
1.95
2.4
1.4
—
—
—
0
0
5
14
3.65
1.62
2.2
1.4
—
—
—
0
0
26
162
1.72
1.62
6.9
4.8
5.4
47.3
ug/l
0.79
26
137
64
498
1.47
1.55
2.8
3.3
—
—
—
0
0
11
53
2.15
1.42
3.8
2.8
4.1
4.1
pmol/l
0.02
11
44
24
153
1.67
1.38
1.8
1.8
—
—
—
0
0
6
24
2.55
1.31
1.0
1.1
—
—
—
0
0
16
93
1.80
1.26
2.5
3.3
56.0
58.2
ml/min/173m2
—
6
40
32
226
1.52
1.22
2.3
2.0
—
—
—
0
0
32
231
1.48
1.11
3.1
1.9
30.2
29.8
s
0.12
32
221
23
155
1.56
1.08
1.9
1.9
—
—
—
0
0
81
699
1.31
0.94
4.9
3.2
62.7
59.2
u/l
0.12
73
637
94
830
1.31
0.92
5.0
3.6
15.6
15.1
pmol/l
1.00
85
717
0
25
0.00
0.79
0.0
1.3
—
1.7
—
0
7
10
60
1.71
0.74
1.7
2.3
—
—
—
0
0
5
25
2.03
0.73
1.2
1.5
—
—
—
0
0
5
25
2.03
0.73
1.2
1.5
—
—
—
0
0
5
26
1.95
0.71
2.4
1.6
—
—
—
0
0
5
27
1.88
0.69
2.2
1.6
—
—
—
0
0
25
190
1.37
0.68
4.4
4.8
32.5
32.1
%
0.05
17
124
5
29
1.75
0.64
2.2
1.6
—
—
—
0
0
17
122
1.44
0.63
1.6
3.3
68.1
66.1
g/l
0.62
17
110
5
30
1.69
0.62
1.4
1.2
—
—
—
0
0
45
379
1.26
0.60
3.1
3.2
1.4
0.4
e6/l
0.56
36
288
8
53
1.53
0.59
2.1
3.4
41.7
37.2
g/l
—
8
46
0
23
0.00
0.58
0.0
1.2
—
—
—
0
0
9
60
1.53
0.55
1.9
3.1
8.6
10.5
g/l
—
9
53
9
61
1.50
0.55
1.9
3.1
2.9
3.1
g/l
—
9
50
48
553
0.81
0.54
5.8
4.7
22.7
21.0
%
0.34
31
282
9
65
1.41
0.51
1.9
3.0
—
—
—
0
0
9
65
1.41
0.51
1.9
3.0
3.4
3.8
g/l
—
9
49
9
65
1.41
0.51
1.9
3.0
7.1
7.5
g/l
—
9
51
7
109
0.63
0.50
1.4
1.5
—
—
—
0
0
34
402
0.81
0.49
3.4
3.2
0.9
0.8
ug/l
0.34
26
285
62
552
1.20
0.49
2.4
2.3
—
—
—
0
0
23
183
1.30
0.48
8.3
7.1
3.5
0.9
mmol/l
2.18
18
146
5
31
1.63
0.43
2.2
1.6
—
—
—
0
0
8
57
1.42
0.43
2.1
3.3
1.3
0.3
g/l
—
8
50
8
58
1.40
0.42
1.8
2.0
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
41
358
1.19
0.39
1.4
1.7
20.8
21.4
nmol/l
0.09
33
297
122
1164
1.18
0.39
25.8
18.2
30.2
27.4
mg/l
0.42
111
969
64
582
1.16
0.38
5.5
4.4
52.5
42.9
ng/l
0.20
55
447
111
1052
1.17
0.38
6.0
4.4
1.9
2.0
mu/l
0.13
99
914
61
554
1.16
0.37
2.2
2.1
102.7
94.0
pmol/l
0.85
42
296
9
124
0.71
0.36
1.1
1.3
—
—
—
0
0
110
1154
0.86
0.36
5.3
5.5
2.4
2.6
mmol/l
1.36
100
1036
64
584
1.16
0.36
5.5
5.5
0.0
0.0
estimate
0.00
18
115
103
1085
0.87
0.36
4.4
4.4
1.3
1.3
mmol/l
0.15
92
965
54
487
1.16
0.36
1.8
2.2
84.9
76.5
nmol/l
0.76
47
418
94
883
1.15
0.35
5.1
4.1
15.5
14.0
mm/h
0.34
84
800
6
43
1.41
0.35
1.3
1.4
—
—
—
0
0
20
164
1.25
0.34
6.0
3.7
—
—
—
0
0
35
306
1.18
0.33
2.0
1.7
1184.5
1138.6
nmol/l
0.14
30
225
107
1121
0.87
0.33
4.7
4.9
1.4
1.4
mmol/l
0.26
97
1005
12
153
0.77
0.32
1.2
1.3
54.1
6.0
u/ml
—
5
54
54
492
1.15
0.31
3.5
3.3
743.3
1535.3
ng/l
1.89
47
415
12
95
1.28
0.27
1.4
1.5
—
—
—
0
0
64
596
1.12
0.26
4.0
4.1
0.0
0.0
estimate
0.00
17
107
63
588
1.12
0.24
4.0
4.1
0.0
0.0
estimate
0.00
17
115
26
294
0.86
0.24
2.0
1.8
426.6
453.3
pmol/l
0.16
20
242
14
166
0.83
0.21
1.1
1.2
48.0
47.0
iu/ml
—
6
57
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
109
1126
0.91
0.20
4.7
4.9
4.3
4.4
mmol/l
0.22
99
1020
12
100
1.22
0.18
1.7
1.9
7.4
12.6
nmol/l
1.87
12
86
8
72
1.12
0.16
2.4
1.3
—
—
—
0
0
49
462
1.09
0.15
4.8
4.4
—
—
—
0
0
117
1142
1.08
0.14
5.6
5.1
6.3
6.2
mmol/l
0.61
106
1020
37
347
1.09
0.12
4.3
4.2
0.0
0.0
estimate
0.00
14
104
36
338
1.08
0.12
2.3
3.0
356.9
7421.7
umol/l
1.50
28
281
5
44
1.14
0.10
5.8
2.4
25.5
24.1
mmol/l
—
5
32
29
272
1.08
0.10
2.0
1.7
1.1
1.5
mg/l
0.73
22
214
5
47
1.07
0.09
2.2
4.3
22.4
35.9
mg/l
—
5
37
5
47
1.07
0.09
2.2
4.3
45.4
231.0
mg/l
—
5
36
5
60
0.83
0.08
2.6
4.1
10.4
1453.8
u/ml
—
5
51
10
88
1.15
0.08
1.7
3.4
0.7
0.2
e6/l
—
10
88
20
215
0.92
0.08
25.7
25.8
1.3
1.4
inr
—
7
21
24
225
1.08
0.08
2.2
2.9
1.3
0.9
e6/l
0.18
15
133
9
84
1.08
0.07
1.9
1.8
—
—
—
0
0
112
1103
1.05
0.07
24.6
17.0
74.6
73.6
ml/min/173m2
0.20
100
897
16
172
0.92
0.06
5.1
9.8
—
—
—
0
0
20
191
1.05
0.03
6.5
7.0
104.1
104.2
mmol/l
0.07
20
186
21
209
1.01
0.00
2.0
2.4
2.2
2.3
g/l
0.14
21
191
22
219
1.01
0.00
2.2
3.2
1.6
1.7
e6/l
0.00
13
129
110
1102
0.99
0.00
8.2
6.5
41.6
41.3
mmol/mol
0.12
99
1010
70
699
1.00
0.00
5.9
5.5
2.3
2.8
ug/l
0.48
61
606
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
3.8
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
3.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
3.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_INSITU_EAR_RESP – Carcinoma in situ of middle ear and respiratory system
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).